[Skip to Content]
[Skip to Content Landing]
Citations 0
Medical News & Perspectives
October 27, 1999

Better Control Coming for Clotting and Bleeding

Author Affiliations

Not Available

Not Available

JAMA. 1999;282(16):1509-1510. doi:10.1001/jama.282.16.1509-JMN1027-3-1

Washington—New methods of controlling the behavior of blood in the human body were reported at the 17th Congress of the International Society on Thrombosis and Hemostasis (ISTH) held here last month. Better treatments for clotting and bleeding disorders were central topics of discussion.

The risk of venous thromboembolism in surgical patients has long been recognized. Now a new study shows that thromboembolism is also a risk in acutely ill medical patients. But an international, multicenter, randomized, double-blind, placebo-controlled trial has shown that a daily dose of 40 mg of enoxaparin (Lovenox, Rhone-Poulenc Rorer), a low molecular weight heparin, reduced the risk of venous thromboembolism in medically treated patients by about one third.